

 Early Warning System

IFC-48756

Joincare



Quick Facts

Countries	China
Specific Location	Henan and Guangdong provinces
Financial Institutions	International Finance Corporation (IFC)
Status	Approved
Bank Risk Rating	B
Voting Date	2024-12-19
Borrower	Joincare Pharmaceutical Group Industry Co., Ltd.
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 130.00 million
Project Cost (USD)	\$ 275.00 million



Project Description

According to the Bank's website, the proposed investment will support Joincare to fund: (i) the expansion for development and production capacity of APIs and finished formulations in Henan and Guangdong provinces, China; and (ii) investment, including working capital needs, related to key therapeutic areas. The additional production capacity created by the Project will enable the Company, given its vertical integration and scale, to produce APIs and intermediates at lower cost and improve the affordability and availability of pharmaceutical products in China and in emerging markets.



Early Warning System Project Analysis

This is a Category B project according to IFC's Policy on Environmental and Social Sustainability (2012). Key E&S issues associated with this Project include: the Company's management and monitoring systems to assess and manage E&S risks and impacts from its operations, and related to the construction of two new facilities; consistent management of labor and working conditions including occupational health and safety; monitoring and management of air emissions, waste and wastewater, and hazardous materials; resource efficiency measures; management of life and fire safety (LFS) and emergency preparedness and response; and stakeholder engagement activities related to E&S aspects.



Investment Description

- International Finance Corporation (IFC)

The Project is estimated to cost US\$275 million and will be funded by the IFC loan of up to US\$100 million equivalent, and the Company's internally generated cashflow.

IFC's Investment as Approved by the Board: Loan 130.0 million (USD)



Private Actors Description

Founded in 1992 and headquartered in Shenzhen, *Joincare Pharmaceutical Group Industry Co., Ltd.* is a diversified pharmaceutical manufacturer of chemical drugs, active pharmaceutical ingredient and intermediates, biological drugs and diagnostic reagents and equipment.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Joincare Pharmaceutical Group Industry Co., Ltd.	Client	-



Contact Information

Joincare Pharmaceutical Group Industry Co., Ltd.

Yifan ZHU

Director

+86 755 86252368

zhuyifan@joincare.com

No. 17 Langshan Road, North District, High-tech Zone, Nanshan District, Shenzhen, Guangdong, China

<https://en.joincare.com/>

ACCESS TO INFORMATION

You can submit a request for information disclosure at: <https://disclosures.ifc.org/#/inquiries>

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org>



Bank Documents

- [Environmental & Social Review Summary \(ESRS\)](#)